HFCAS OpenIR
(本次检索基于用户作品认领结果)

浏览/检索结果: 共3条,第1-3条 帮助

限定条件        
已选(0)清除 条数/页:   排序方式:
CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2022
作者:  Cao, Jiang-yan;  Qi, Shuang;  Wu, Hong;  Wang, Ao-li;  Liu, Qing-wang;  Li, Xi-xiang;  Wang, Bei-lei;  Ge, Juan;  Zou, Feng-ming;  Chen, Cheng;  Wang, Jun-jie;  Hu, Chen;  Liu, Jing;  Wang, Wen-chao;  Liu, Qing-song
收藏  |  浏览/下载:104/0  |  提交时间:2022/03/28
HER2  breast cancers  gastric cancers  irreversible inhibitor  drug resistance  
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode 期刊论文
ONCOTARGET, 2017, 卷号: 8, 期号: 11, 页码: 18359-18372
作者:  Hu, Chen;  Wang, Aoli;  Wu, Hong;  Qi, Ziping;  Li, Xixiang;  Yan, Xiao-E;  Chen, Cheng;  Yu, Kailin;  Zou, Fengming;  Wang, Wenchao;  Wang, Wei;  Wu, Jiaxin;  Liu, Juan;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Jing;  Liu, Qingsong
浏览  |  Adobe PDF(6153Kb)  |  收藏  |  浏览/下载:183/48  |  提交时间:2018/07/04
Egfr  Egfrt790m  Nsclc  Kinase Inhibitors  Drug Resistance  
Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma 期刊论文
ACS Chem. Biol, 2014, 卷号: 9, 期号: 5, 页码: 1086-1091
作者:  Hong Wu;  Wenchao Wang;  Feiyang Liu;  Yongfei Chen;  Binhua Li;  Aoli Wang;  Beilei Wang;  Zheng Zhao;  Chen Hu;  Hong Li;  Jing Liu;  Qingsong Liu等
浏览  |  Adobe PDF(2079Kb)  |  收藏  |  浏览/下载:38/24  |  提交时间:2016/11/22